- Home
- ANNX vs SABA Comparison
ANNX vs SABA Comparison
Compare ANNX & SABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANNX
- SABA
- Stock Information
- Founded
- ANNX 2011
- SABA 1988
- Country
- ANNX United States
- SABA United States
- Employees
- ANNX N/A
- SABA N/A
- Industry
- ANNX Biotechnology: Pharmaceutical Preparations
- SABA
- Sector
- ANNX Health Care
- SABA
- Exchange
- ANNX Nasdaq
- SABA Nasdaq
- Market Cap
- ANNX 263.3M
- SABA 254.3M
- IPO Year
- ANNX 2020
- SABA N/A
- Fundamental
- Price
- ANNX $2.42
- SABA $9.43
- Analyst Decision
- ANNX Strong Buy
- SABA
- Analyst Count
- ANNX 4
- SABA 0
- Target Price
- ANNX $12.50
- SABA N/A
- AVG Volume (30 Days)
- ANNX 1.7M
- SABA 290.0K
- Earning Date
- ANNX 08-11-2025
- SABA 01-01-0001
- Dividend Yield
- ANNX N/A
- SABA 12.91%
- EPS Growth
- ANNX N/A
- SABA N/A
- EPS
- ANNX N/A
- SABA N/A
- Revenue
- ANNX N/A
- SABA N/A
- Revenue This Year
- ANNX N/A
- SABA N/A
- Revenue Next Year
- ANNX N/A
- SABA N/A
- P/E Ratio
- ANNX N/A
- SABA N/A
- Revenue Growth
- ANNX N/A
- SABA N/A
- 52 Week Low
- ANNX $1.29
- SABA $3.64
- 52 Week High
- ANNX $7.85
- SABA $4.42
- Technical
- Relative Strength Index (RSI)
- ANNX 47.32
- SABA 58.58
- Support Level
- ANNX $2.29
- SABA $9.17
- Resistance Level
- ANNX $2.62
- SABA $9.37
- Average True Range (ATR)
- ANNX 0.17
- SABA 0.13
- MACD
- ANNX -0.01
- SABA 0.01
- Stochastic Oscillator
- ANNX 37.74
- SABA 80.56
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
About SABA Saba Capital Income & Opportunities Fund II Shares of Beneficial Interest
Saba Capital Income & Opportunities Fund II is a closed-end fund. The company seeks high current income, with a secondary goal of capital appreciation. The fund invests in fixed income markets across the globe.